Details for Patent: 10,695,339
Which drugs does patent 10,695,339 protect, and when does it expire?
Patent 10,695,339 protects COBENFY and is included in one NDA.
This patent has twenty-eight patent family members in fourteen countries.
Summary for Patent: 10,695,339
| Title: | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| Abstract: | The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline salt and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period, the central nervous system disorder being selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline salt. |
| Inventor(s): | Eric Elenko, Philip E. Murray, III, Andrew C. Miller |
| Assignee: | Puretech Health LLC , Puretech Management Inc |
| Application Number: | US16/444,206 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,695,339
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-myers | COBENFY | trospium chloride; xanomeline tartrate | CAPSULE;ORAL | 216158-001 | Sep 26, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF SCHIZOPHRENIA IN ADULTS | ⤷ Start Trial | ||||
| Bristol-myers | COBENFY | trospium chloride; xanomeline tartrate | CAPSULE;ORAL | 216158-002 | Sep 26, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF SCHIZOPHRENIA IN ADULTS | ⤷ Start Trial | ||||
| Bristol-myers | COBENFY | trospium chloride; xanomeline tartrate | CAPSULE;ORAL | 216158-003 | Sep 26, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF SCHIZOPHRENIA IN ADULTS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,695,339
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2804215 | ⤷ Start Trial | |||
| Denmark | 3061821 | ⤷ Start Trial | |||
| European Patent Office | 2456868 | ⤷ Start Trial | |||
| European Patent Office | 3061821 | ⤷ Start Trial | |||
| European Patent Office | 3646870 | ⤷ Start Trial | |||
| European Patent Office | 4803073 | ⤷ Start Trial | |||
| Spain | 2742728 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
